Oramed Pharmaceuticals, Inc., a prominent player in the pharmaceutical sector, recently disclosed its quarterly financial results, revealing a complex financial landscape as the company continues to innovate in the realm of oral drug delivery. Headquartered in Jerusalem, Israel, and listed on the Nasdaq, Oramed is dedicated to developing oral delivery solutions, with a particular focus on orally ingestible insulin capsules for diabetes treatment.
In its latest Form 10-Q filed on May 19, 2026, Oramed reported a net cash outflow from operating activities, alongside negative cash flows from both investing and financing activities. This confluence of factors led to a decrease in cash and cash equivalents from the beginning to the end of the period. Despite these challenges, the company’s revenues for the quarter were minimal, and it recorded a net operating loss. However, this loss was partially mitigated by significant financial income and other non-cash items.
A pivotal aspect of Oramed’s recent financial activities is its transaction with Lifeward Ltd. This strategic move involved transferring Oramed’s POD™ technology platform to a newly established Israeli subsidiary. In return, Oramed received shares, warrants, and revenue-sharing arrangements. Additionally, the transaction resulted in the creation of a senior secured convertible note, which will remain unissued until specific performance milestones are achieved.
The company’s balance sheet reflects a modest asset base, with a noted decline in cash and short-term investments compared to the previous quarter. Despite these financial headwinds, Oramed’s equity section shows a reduction in its accumulated deficit. Share-based compensation continues to be recorded as a standard accounting practice, with no new regulatory or accounting changes materially impacting the company’s financial position during the reporting period.
Oramed’s market capitalization stands at approximately $187.67 million, with a close price of $4.33 as of May 18, 2026. The company’s price-to-earnings ratio is 3.11, indicating investor sentiment and market expectations. Over the past year, Oramed’s stock has experienced volatility, with a 52-week high of $5.01 on May 10, 2026, and a low of $1.98 on August 14, 2025.
As Oramed navigates its financial challenges, the company remains focused on its core mission of advancing oral drug delivery technologies. The strategic transaction with Lifeward Ltd. underscores Oramed’s commitment to leveraging its innovative platforms to achieve long-term growth and success in the competitive pharmaceutical landscape.
